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ABSTRACT: InJune2015, theNational InstitutesofHealth(NIH)releasedaGuidenotice(NOT-OD-15-102) thathighlighted
theexpectationof theNIHthat thepossible roleofsexasabiologicvariablebefactored into researchdesign,analyses, and
reportingofvertebrateanimalandhumanstudies.Anticipatingtheseguidelines, theNIHOfficeofResearchonWomen’s
Health, in October 2014, convened key stakeholders to discuss methods and techniques for integrating sex as a biologic
variable in preclinical research. The workshop focused on practical methods, experimental design, and approaches to
statistical analyses in the use of both male and female animals, cells, and tissues in preclinical research. Workshop
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Sex, defined as being XY or XX, is a construct derived from
chromosomal complement, is associated with biologic
functions (1), and is an important biologic variable in pre-
clinical research. Recognizing this fact is vital because pre-
clinical data inform the premise and design of clinical
studies. Historical reliance on male vertebrate animals (e.g.,
rats andmice) inpreclinical research (2, 3) has resulted in the
generation of incomplete data available to guide clinical
trials that include female participants. This is particularly
problematic in view of current knowledge that sex affects
health status, including disease presentation, pathophysi-
ology, and therapeutic response. The National Institutes of
Health (NIH) have re-emphasized the importance of rigor
and transparency to reproducibility, including appropriate
accounting for thepotential influenceof sexonexperimental
outcomes in preclinical research (4). NIH has underscored
the need to study males and females in animal, tissue, and
cell studies (4). In June 2015, theNIHreleasedaGuidenotice,
“Consideration of Sex as a Biologic Variable inNIH-funded
Research,”which sets forth the expectation that sex will be
factored into research design, analyses, and reporting in
studies of vertebrate animals and humans (5).
In anticipation of NIH guidelines and as part of an on-
going conversation with investigators, the NIH Office of
Research onWomen’sHealth convened key stakeholders in
October 2014 to discuss methods and techniques for in-
tegratingsexasabiologicvariable inpreclinical research.The
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workshop had a dual focus on sharing research results as
well as lessons learned and promoting discussion on the
importance of considering sex as a biologic variable in pre-
clinical research.Theworkshopincluded4scientific sessions:
Session 1: The concept of including male and female
subjects in studies.
Session 2: What is the impact of including or not
including sex as a basic biologic variable?
Session 3: Practical methods to integrate the biologic
variable sex intro research projects.
Session 4: Cultivating a culture of “sex matters”
across multiple disciplines.
Several opportunities for immediate action were noted
and are expounded upon in this publication, including
decreasing variability via appropriate experimental de-
sign, employing factorial design and other methods to
analyze multiple variables, and collecting and reporting
sex-aggregated data. The workshop video cast and sum-
mary may be found at: http://orwh.od.nih.gov/sexinscience/
researchtrainingresources/methodstechniquesbiovar.asp. This
paper builds on key elements that were derived from the
workshop and serves as a primer to help orient investi-
gators to approaches for considering sex as a biologic
variable in preclinical research.
IMPORTANCE OF INCLUDINGMALE AND FEMALE
ANIMALS IN RESEARCH
The concept that both sexes should be considered in pre-
clinical research is not new. A report published in 2001 by
the Institute of Medicine Committee, Understanding the Bi-
ology of Sex and Gender Differences, recommended: 1) inclu-
sion of sex as a basic variable in biomedical research 2), use
of human-relevant research models to assess sex-related
differences at levels of organization that ranged from the
molecular to the whole organism, and 3) consideration of
the entire lifespan of the organism (1). The biologic basis for
this recommendation is incontrovertible: sex is established
genetically at conception, sexual differentiation ensues, and
intrinsic existence and extrinsic interactions of an organism
are mediated by sex throughout life. Nevertheless, recom-
mendations to include both female and male animals in
preclinical research have been incompletely embraced by
the research community, as evidenced by the continuing
general exclusion of female animals from preclinical re-
search. Furthermore, general guidance for such imple-
mentationhasnotbeenuniformlydevelopedorapplied (3).
POTENTIAL WAYS TO CONSIDER SEX AS A
VARIABLE IN PRECLINICAL RESEARCH
Consider sex influences
NIH policy on consideration of sex as a biologic variable
is a component of an NIH initiative to enhance the repro-
ducibility of preclinical research via rigor and transparency
and is grounded in the guiding principle of studying
both sexes in biomedical research. NIH expects that sex as a
biologic variable will be accounted for in design, analysis,
and reportingof research in vertebrate animals andhumans.
In particular, this approach serves to expand the foundation
of knowledge about male and female biology as well as to
enhance the understanding of the applicability of research
findings to males and females. The policy does not require
use of a specific experimental design or a defined statistical
analytic approach (6); rather, it provides the flexibility for
developmentofappropriatedesignandanalysesonthebasis
of the research question and the scientific context.
In considering how sex may influence the biologic
process under study, one might begin by considering the
translational context and clinical relevance by asking the
following:
Is it known that the disease process or event applies
to only males or females?
Is there evidence of male/female differences in
humans in the incidence or prevalence, presenta-
tion, treatment response, or morbidity or mortality
of the condition or disease of interest?
If there is no difference reported in the literature, is
this because it has not been studied or reported?
How might sex influence the processes, pathways,
and/or phenomena under study?
Incorporation of sex as a biologic variable can enhance
research in several ways. In the simplest way, it should
lead to better reporting the sex of animals and cells used
in research, which would at least improve the chance
to appreciate which sex was studied. A second way
would be the study of outcome measures (e.g., effects
of treatments) separately in each sex so that treatment
effects would be more broadly known and could be
applied to clinical studies of each sex. The third way is
to compare outcome measures in females and males
directly—and statistically—to establish whether there
is a sex difference in treatment. Finding significant sex
differences in treatment variables has the advantage
that well-known sex-biasing factors (hormones, sex
chromosomes, and environments) immediately be-
come interesting candidates for factors thatmodulate or
condition effects of treatment.
Studies of animal models can be particularly informa-
tive compared with studies of humans, because the sex
variable can be broken down into its constituent parts,
which are individual sex-biasing variables that affect
physiology and disease. There are 2 variables that are
constitutivelydifferentbetweenmales and females: thesex
chromosome complement (XX vs. XY) and gonadal hor-
mones (ovarian vs. testicular secretions). In animal studies,
each of these factors can often be manipulated indepen-
dentlyof theothers todetermine the specific effectsof each.
There are some conditions in humans that result from al-
tered expression of X and Y chromosomes; however, dif-
ferentiating effects of chromosomes and hormones in
humans is difficult, and, thus, animal studies provide an
important window into the role of each separate sex-
biasing factor.When a sex-biasing factor, such as estradiol
or an X gene that is always expressed higher in XX than in
XY individuals, is found to reduce a disease process, the
sex-biasing factor itself and the downstream gene path-
ways that it influences become a possible therapeutic or
drug target that can alleviate disease.
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Consider the role of sex chromosomes
Female and male cells differ in their complement of sex
chromosomes (XX vs. XY), which causes an inherent sexual
imbalanceof expressionofXandYgenes invirtuallyall cells
of the body. Although this imbalance was historically con-
sidered to have little effect in creating distinctions between
males and females in physiology and disease, in recent
years, sex chromosome effects have been shown to be sur-
prisingly large in several mouse models of disease (7–10).
Mouse models exist that are suitable for the detection of
effects of XX vs. XY sex chromosome complement, in-
dependent of their role in causing differences in gonadal
hormone levels betweenmales and females (11, 12). Studies
of thesemodelshavealreadyprovidedevidence thatbothX-
and Y-encoded genes and mechanisms can protect from
disease inmice.Thenext step is todiscover thespecificXorY
genes that are protective and to understand the gene path-
ways that they regulate as a strategy for uncovering novel
mechanisms that couldbe enhanced toamelioratedisease in
both sexes. Because of the novelty of sex chromosome
mechanisms, much remains to be learned.
Consider the role of sex hormones
Sex hormones—androgens (testosterone and its metabo-
lite, dihydrotestosterone), pregnanes (progesterone and
allopregnanolone), and estrogens (estradiol, estriol, and
estrone)—are generally considered to be the steroidal
hormones that are produced by the gonads, adrenal
glands, and certain tissues, such as the liver or brain. The
term sex hormone is nearly always synonymous with sex
steroid or gonadal steroid. The glycoprotein hormones—
luteinizing hormone, follicle-stimulating hormone, and
gonadotropin-releasing hormone—are produced by the
anterior pituitary gland and are usually not regarded as
sex hormones, although they play major roles in the re-
production and development of secondary sex character-
istics in both males and females (13).
Sex hormones are crucial for the development and
function of the body as well as for the regulation of sexual
differentiation, secondary sex characteristics, and sexual
behavior patterns (13). Although estradiol, an estrogen, and
progesterone, a pregnane, are generally considered to be
female’ sexhormonesand testosterone theale’ sexhormone,
all 3 sexsteroidsarepresent inbothmalesandfemales,albeit
at different levels in the 2 sexes. Production of sex steroids
also varies across the lifespan and reproductive life stage.
Sex hormone receptors exist throughout the body,
which suggests that hormones affect a myriad of body
tissuesdirectly. Estrogensmost often formcomplexeswith
their receptors and various transcription factors, thereby
interacting directly with the genome and influencing a
broad range of cellular events (14). Studies of males and
females and the role of sex steroids are most often un-
dertaken by using experimental animal models. One way
to begin to elucidate the role of sex hormones is to remove
the gonads of both male and female adult animals and
then perform comparisons. Another approach is to pro-
vide exogenous hormones to gonadectomized animals
(15). If a difference between males and females persists in
the absence of gonadal hormones, one would then con-
sider whether this distinction is attributable to develop-
mental or chromosomal effects (16).
Consider the role of sex and gender
assumptions in study design
Gender refers to the behavioral norms and, in the case of
humans, attitudes that influence individual action, expec-
tations, and experiences. For both humans and other ani-
mals, gender is shaped by biology, environment, and
experience. Researchers’ gender assumptions may play an
important role in the design of animal studies. Conceptions
of gender may influence how investigators construct bi-
ologic hypotheses and interpret outcomes. For example,
assumptions about the role of sex hormones or prevalence
of a disease state inmales or femalesmay influence choices
concerning which sex to test. Erroneous assumptions in
participant selection can have cascading consequences for
the study as awhole. For example, researchersmay assume
that testosterone is a male hormone, even though andro-
gens also have natural effects in females. Such assumptions
may lead to a decision to test the relationship between tes-
tosteroneandachosenvariableonly inmaleparticipants. In
this case, potentially important information is ignored
about the contributions of androgens and androgen re-
ceptors in females.Alternatively, effects of aromatization of
testosterone to estrogen in males has effects on bone, but
other tissue-specific conversions may have implications in
the heart andbrain.Moreover, therapies thatmight involve
administration of androgens to either sex might benefit
from being considered in a larger context than the idea that
androgens can only make females more like males, espe-
cially if the response of females to androgens differs from
thatofmales. Furthermore, assumption thatbreast cancer is
a female disease has led to the development of female-only
animal models, which limits the opportunity to better un-
derstand breast cancer in males (17, 18).
IMPLEMENTING EXPERIMENTAL DESIGN
The purpose of preclinical research—using animal model
systems, tissues, or cells—is to model and characterize hu-
man disease processes, uncover pathogenic pathways,
identify and/or interrogate potential therapeutic targets,
and test therapeutic strategies/interventions. However, in-
vestigators have often been unable to reproduce promising
preclinical research results, with a recent report (19) esti-
mating that roughly53%of irreproduciblepreclinical results
were causedby root factors categorized as studydesign and
data analysis and reporting, which resulted in considerable
loss of economic impact on biomedical research. A plethora
of variables (e.g., sex of experimental material, age, housing
type, genes, environment, health status, time of day, sex
of experimenter, circadian or diurnal hormone cycles in
males and females, noise level, order of testing of multiple
dependent variables, laboratory protocol error, etc.) can in-
duce variability in outcome of studies (20). Hence, critical
aspects of experimental design for animal research, such
as sex of participant, time of day, room temperature, test
article, administrationmethod, etc., shouldbe systematically
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addressed and controlled to avoid generating faulty results
that lead to erroneous conclusions. In this section, in-
corporating both sexes and controlling for sex will be
addressedby focusingonways to employexperimental and
statistical control in preclinical study designs.
Experimental hypotheses may address the direct
comparison of males vs. females to detect a difference
between them, they may address the influence of an
intervention on each sex, or they may address the in-
teraction of sex with an intervention (i.e., Does the in-
tervention work equally well in males and females or
does being male or female influence the manner in
which the intervention works?).
Explore effects in males and in females
To begin investigation of the potential influence of sex as a
biologic variable when little is known about the influence
of sex in the context of a particular animal model and
research question, males and females can be incorporated
into experiments with a modest increase in the total
number of animals (21). For example, if an investigator
randomly assigned 8 male rats to the control group and 8
male rats to the treatment group, he/she might consider
using 10male rats and 10 female rats, randomly assigning
them in comparable numbers to control (5 males and 5
females) and treatment (5 males and 5 females) groups.
The investigator might want to explore the potential
effectivenessof a treatment inbothmalesand females.Asa
first step, an investigator may start by examining results
for each sex—results analyzed separately formales and for
females. For example, the investigator might begin by
assessing overall measures of response (e.g., peak re-
sponse, area under the curve, clearance) in males and fe-
males (22). Such anapproachmayprovide an indicationof
a sex difference; however, if no obvious sex difference is
detected, one cannot conclude that there are no sex dif-
ferences because the study was not powered a priori to
detect sex differences or different regulatory processes
may result in similarities in outcomes (compensation) in
both sexes. Discussion of the limitations of study design
should be included with interpretation of study results.
Further studies designed and powered to detect sex dif-
ferences would be needed. This approach is sometimes
used in toxicology studies and in settings inwhich animals
are not readily available in sufficient numbers (e.g., non-
human primates).
This approach—using both males and females
without much increase in total number of animals—
can show a treatment effect when there is little sex
difference in the effect of treatment; however, when
the treatment is effective only in one sex or has oppo-
site effects in the 2 sexes, this approach can prevent
discovery of treatment effects because it is under-
powered. This approach, however, does give an initial
assessment of the effect size of both variables, sex and
treatment, and provides a foundation for a power
analysis to determine what group sizes would be
needed to demonstrate statistically significant effects
of each variable or their interaction.
Accounting for sex as a variable via
factorial design
Males and females could be incorporated into a factorial
design that allows the concurrent examination of both a
participant variable, such as sex and another variable, and
also an assessment of the interaction of sex with another
independent variable on the outcome measure. In a facto-
rial design, statistical analyses will present the effects of
each independent variable (sex, other variable) on the
outcomemeasurement regardlessof the impactof theother
variable as a main effect andwill present the interaction of
sex and the other variable. An interaction is detected if one
independent variable alters the effect of the other.
For example, in an experimental design with a 2-level
factor for treatment [ethanol at 5 mg/kg or no ethanol
(0 mg/kg control solution)] and a 2-level factor for sex
(male, female), one canenvision a factorial design inwhich
8 animals are randomly placed into each of 4 groups/
conditions (male-ethanol, male-control, female-ethanol,
female-control) for a total of 32 animals in the experiment.
With 16 male animals and 16 female animals, a test of the
outcomebetweensexesmaybesufficiently robust todetecta
difference, if one exists, on the sex factor depending on
variability in each sex and the effect size: this would be a
maineffectof sex.Similarly, if 16animals receiveethanoland
16 animals receive the control solution, a test of the outcome
maybesufficiently robust todetectadifference for treatment
as the factor: this would be a main effect of treatment.
However, the truevalueof thefactorialdesigninvolvesthe
ability,viaapplicationof the2-wayANOVA,todeterminethe
extent to which the outcome is altered by being male or fe-
maleandreceiving theethanolorcontrol solution; this isa test
of the interaction, which is achievable by use of factorial de-
sign (see Fig. 1). Statistical test of the interaction will show
howthemeansof the4groupsdiffer andwhetherbeingmale
or female changes the effect of ethanol vs. control conditions.
The potential return on investment with a factorial de-
sign is attractive, because: 1) variability as a result of each
factor is parsed out before assessment of the interaction; 2)
conclusions about outcome canbe refined to a specific level
(e.g., drug dose if multiple drug doses are included) to ei-
ther male or female participants, thus eliminating the need
to perform the same studywith the samemultiple levels in
the future; 3) the number of animals may potentially be
reduced in future studies as a result of the statistical
parceling of error variance; and 4) interpretation of out-
come is clear because of powerful control over variance.
SEX-BASED ANALYSIS AND REPORTING
AS A CONSIDERATION IN
PRECLINICAL INVESTIGATIONS
Sex-disaggregated data analysis and characterization of the
effect of a treatment on a selected outcome measure sepa-
rately in each sex can enhance understanding of underlying
mechanisms in males and females. In contrast, analyzing
aggregate data frommales and females combinedmay lead
to false conclusions—for example, when a response is in
oppositedirections inmales and females. Similarly, if a result
is qualitatively different in males and females (e.g., different
32 Vol. 31 January 2017 MILLER ET AL.The FASEB Journal x www.fasebj.org
areas of the brain affected in males vs. females), analyzing
data inaggregatemay lead toerroneousconclusions forboth
sexes. Furthermore, analyzing results in one sex, but gener-
alizing results to both males and females, may result in er-
roneous conclusions.
Analyses are based on/driven by the research question
and studydesign. It is important to be transparent about the
limitations of study designs. For example, presentation of
descriptive analyses of findings in males and females (e.g.,
outcome measure, mean, median, mode, range, and SD in
males and females) should not be interpreted as proving or
disproving sex differences in studies that have not been
designed to detect such differences. Nevertheless, given the
importance of sex-specific data, even when comparative
analysis cannot be performed as a result of design limita-
tions, sex-disaggregateddata should be reported (e.g., sex of
research material, results in males, and results in females)
when possible. It is equally important that limitations of
Figure 1. Schematic of a 232
factorial design showing test of the
main effects of sex and drug
treatment. Various possible out-
comes are shown. The top line of
outcomes shows a ﬁnding of signif-
icant main effect only of drug, a
signiﬁcant main effect only of sex,
and signiﬁcant main effects of both
without interaction. The bottom
line shows 3 different outcomes
that are all signiﬁcant interactions
of sex and drug, which means that
the effect of drug depends on sex
and, reciprocally, the effect of sex
depends on the level of drug. DV,
dependent variable.
TABLE 1. Summary of ways to consider sex as a variable in preclinical research
Consideration Description Reference










Consider sex and gender
assumptions in design
Design of animal study 6
Choice of animal model 16
Choice of animals to study
(male, female, both)
20
Analysis and reporting Sex of research material 2
Sex-disaggregated data 22
Report by sex in publications
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study designs be acknowledged, that findings from one sex
not be applied to the otherwithout testing, and that data are
interpreted appropriately in the context of the potential in-
fluence of sex as a basic biologic variable. Sex influences that
are detected in preliminary studies and analyses may pro-
vide useful insights into our understanding and inform fu-
ture investigations. A summary of considerations for the
research process has been provided (Table 1).
CONCLUSIONS
Sex is an important biologic variable. Preclinical research
studies that incorporate both sexes are crucial to recog-
nizing the applicability of study findings and to informing
the translation of research frombasic scientific discovery to
drug development and testing of therapeutics. Studying
both sexes in preclinical research is good science. Including
both sexes in preclinical studies and experimental designs
that appropriately account for sex as a biologic variable
promotes understanding of experimental outcomes for
males and females. Translation of such results to clinical
testing advances us one step closer to evidence-based ap-
propriate treatments for both men and women.
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